Twist Bioscience Preclinical Data Detailing Discovery Of Antibody Targeting Emerging Checkpoint Inhibitor Published In The Journal PLOS ONE
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience Corporation (NASDAQ:TWST) announced the publication of a study in PLOS ONE detailing the discovery of TB206-001, a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor-suppressing activity. TB206-001 is available for out-licensing.
June 06, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's publication of preclinical data on TB206-001, a high-affinity antibody targeting A2AR, could enhance its position in cancer immunotherapy. The availability of TB206-001 for out-licensing may generate new revenue streams.
The publication of promising preclinical data on TB206-001 positions Twist Bioscience as a key player in cancer immunotherapy. The availability of the antibody for out-licensing could attract partnerships and generate additional revenue, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100